Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2010, Vol. 4 Issue (4) : 378-384     DOI: 10.1007/s11684-010-0230-3
Research articles |
The value of epigenetic markers in esophageal cancer
Xiao-Mei ZHANG,Ming-Zhou GUO,
Department of Gastroenterology & Hepatology, Chinese PLA General Hospital, Beijing 100853, China;
Download: PDF(116 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  Developing esophageal cancer is a multi-step process that begins with the accumulation of genetic and epigenetic alterations, and leads to the activation of oncogenes and the inactivation or loss of tumor suppressor genes (TSG). In addition to genetic alteration, epigenetic modifications, and in particular DNA methylation, are recognized as a common molecular alteration in human tumors. In esophageal cancer, aberrant methylation of promoter regions occurs not only in advanced cancer, but also in premalignant lesions. DNA methylation is related to survival time and sensitivity of chemoradiotherapy. This review is mainly focused on epigenetic changes in esophageal cancer and the value of early detection for patient prognosis, treatment choices, and potential targeting therapy.
Keywords epigenetics      DNA methylation      esophageal cancer      dysplasia      
Issue Date: 05 December 2010
URL:     OR
Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin, 2005, 55(2): 74―108
PMID: 15761078
Hu N, Dawsey S M, Wu M, Bonney G E, He L J, Han X Y, Fu M, Taylor P R. Family history of oesophageal cancer in Shanxi Province. Int J Epidemiol, 1992, 21(5): 877―822
PMID: 1468848
Yang C S. Research on esophageal cancer in China: a review.Cancer Res, 1980, 40(8 Pt 1): 2633―2644
PMID: 6992989
Taylor P R, Dawsey S M, Hu N, Albanes D, Wu M. Nutritional interventionto prevent hereditary cancer.J Natl CancerInst Monogr, 1995, (17): 43―47
PMID: 8573452
Carter C L, Hu N, Wu M, Lin P Z, Murigande C, Bonney G E. Segregation analysis of esophageal cancer in 221 high-risk Chinesefamilies.J Natl Cancer Inst, 1992, 84(10): 771―776
PMID: 1573663
Mu?oz N. Epidemiological aspects of oesophageal cancer.Endoscopy, 1993, 25(9): 609―612
PMID: 8119215
Nielsen N H, Mikkelsen F, Hansen J P. Oesophageal cancer in Greenland:selected epidemiological and clinical aspects.J Cancer Res Clin Oncol, 1979, 94(1): 69―80
PMID: 381317
Cameron A J. Epidemiology of columnar-lined esophagus and adenocarcinoma.Gastroenterol Clin North Am, 1997, 26(3): 487―494
PMID: 9309399
Okano J, Snyder L, Rustgi A K. Genetic alterations in esophageal cancer.Methods Mol Biol, 2003, 222: 131―145
PMID: 12710684
Vogelstein B, Kinzler K W. The multistep nature of cancer.TrendsGenet, 1993, 9(4): 138―141
PMID: 8516849
Zhang W, Gl?ckner S C, Guo M, Machida E O, Wang D H, Easwaran H, Van Neste L, Herman J G, Schuebel K E, Watkins D N, Ahuja N, Baylin S B. Epigenetic inactivation of the canonical Wnt antagonistSRY-box containing gene 17 in colorectal cancer.Cancer Res, 2008, 68(8): 2764―2772
PMID: 18413743
Wang J S, Guo M, Montgomery E A, Thompson R E, Cosby H, Hicks L, Wang S, Herman J G, Canto M I. DNA promoter hypermethylation of p16 and APC predictsneoplastic progression in Barrett's esophagus.Am J Gastroenterol, 2009, 104(9): 2153―2160
PMID: 19584833
Carmona F J, Esteller M. Epigenomics of human colon cancer. MutatRes, 2010, 693(1―2):53―60
PMID: 20691710
Mokrowiecka A, Wierzchniewska-?awska A, Smolarz B, Romanowicz-Makowska H, Malecka-Panas E. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence]. Pol Merkur Lekarski, 2009, 26(155): 385―389
PMID: 19606680
Kohler E M, Brauburger K, Behrens J, Schneikert J. Contribution of the 15 amino acid repeats of truncatedAPC to beta-catenin degradation and selection of APC mutations incolorectal tumours from FAP patients.Oncogene, 2010, 29(11): 1663―1671
PMID: 19966865
Holliday R. The inheritance of epigenetic defects.Science, 1987, 238(4824): 163―170
PMID: 3310230
Jones P A, Baylin S B. The fundamentalrole of epigenetic events in cancer.NatRev Genet, 2002, 3(6): 415―428
PMID: 12042769
Riggs A D, Pfeifer G P. X-chromosome inactivation and cell memory.Trends Genet, 1992, 8(5): 169―174
PMID: 1369742
Ali A B, Iau P T, Sng J H. Cancer-specific methylation in the BRCA1promoter in sporadic breast tumours. MedOncol, 2010Feb5. DOI: 10.1007/S12032-010-9438-Y

doi: 10.1007/S12032-010-9438-Y
Merlo A, Herman J G, Mao L, Lee D J, Gabrielson E, Burger P C, Baylin S B, Sidransky D. 5′ CpG island methylation is associatedwith transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1in human cancers.Nat Med, 1995, 1(7): 686―692
PMID: 7585152
Guo M, House M G, Suzuki H, Ye Y, Brock M V, Lu F, Liu Z, Rustgi A K, Herman J G. Epigenetic silencing of CDX2 is a feature of squamous esophagealcancer.Int J Cancer, 2007, 121(6): 1219―1226
PMID: 17534889
Guo M, House M G, Akiyama Y, Qi Y, Capagna D, Harmon J, Baylin S B, Brock M V, Herman J G. Hypermethylation of the GATA gene family in esophageal cancer.Int J Cancer, 2006, 119(9): 2078―2083
PMID: 16823849
Aguilera O, Fraga M F, Ballestar E, Paz M F, Herranz M, Espada J, García J M, Mu?oz A, Esteller M, González-Sancho J M. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1)gene in human colorectal cancer.Oncogene, 2006, 25(29): 4116―4121
PMID: 16491118
Martinez R, Setien F, Voelter C, Casado S, Quesada M P, Schackert G, Esteller M. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8is a common hallmark of relapsed glioblastoma multiforme.Carcinogenesis, 2007, 28(6): 1264―1268
PMID: 17272309
Blanco D, Vicent S, Fraga M F, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, Lecanda F, Montuenga L M. Molecular analysis of a multisteplung cancer model induced by chronic inflammation reveals epigeneticregulation of p16 and activation of the DNA damage response pathway.Neoplasia, 2007, 9(10): 840―852
PMID: 17971904
Yue W, Sun Q, Dacic S, Landreneau R J, Siegfried J M, Yu J, Zhang L. Downregulationof Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer.Carcinogenesis, 2008, 29(1): 84―92
PMID: 18048388
Lee B B, Lee E J, Jung E H, Chun H K, Chang D K, Song S Y, Park J, Kim D H. Aberrant methylation of APC, MGMT, RASSF2A,and Wif-1 genes in plasma as a biomarker for early detection of colorectalcancer.Clin Cancer Res, 2009, 15(19): 6185―6191
PMID: 19773381
Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, Song X, Lesche R, Liebenberg V, Ebert M, Molnar B, Grützmann R, Pilarsky C, Sledziewski A. DNA methylation biomarkers for blood-based colorectalcancer screening.Clin Chem, 2008, 54(2): 414―423
PMID: 18089654
Atherfold P A, Jankowski J A. Molecular biology of Barrett's cancer.Best Pract Res Clin Gastroenterol, 2006, 20(5): 813―827
PMID: 16997163
Dulai G S, Guha S, Kahn K L, Gornbein J, Weinstein W M. Preoperative prevalence ofBarrett's esophagus in esophageal adenocarcinoma: a systematicreview.Gastroenterology, 2002, 122(1): 26―33
PMID: 11781277
Corley D A, Levin T R, Habel L A, Weiss N S, Buffler P A. Surveillance and survivalin Barrett's adenocarcinomas: a population-based study.Gastroenterology, 2002, 122(3): 633―640
PMID: 11874995
McManus D T, Olaru A, Meltzer S J. Biomarkers of esophageal adenocarcinomaand Barrett's esophagus.Cancer Res, 2004, 64(5): 1561―1569
PMID: 14996709
Bian Y S, Osterheld M C, Fontolliet C, Bosman F T, Benhattar J. p16 inactivation by methylation of the CDKN2A promoter occurs earlyduring neoplastic progression in Barrett's esophagus.Gastroenterology, 2002, 122(4): 1113―1121
PMID: 11910361
Wong D J, Paulson T G, Prevo L J, Galipeau P C, Longton G, Blount P L, Reid B J. p16(INK4a) lesions are common, early abnormalities thatundergo clonal expansion in Barrett's metaplastic epithelium.Cancer Res, 2001, 61(22): 8284―8289
PMID: 11719461
Klump B, Hsieh C J, Holzmann K, Gregor M, Porschen R. Hypermethylation of the CDKN2/p16promoter during neoplastic progression in Barrett's esophagus.Gastroenterology, 1998, 115(6): 1381―1386
PMID: 9834265
Wong D J, Barrett M T, St?ger R, Emond M J, Reid B J. p16INK4apromoter is hypermethylated at a high frequency in esophageal adenocarcinomas.Cancer Res, 1997, 57(13): 2619―2622
PMID: 9205067
Eads C A, Lord R V, Wickramasinghe K, Long T I, Kurumboor S K, Bernstein L, Peters J H, DeMeester S R, DeMeester T R, Skinner K A, Laird P W. Epigeneticpatterns in the progression of esophageal adenocarcinoma.Cancer Res, 2001, 61(8): 3410―3418
PMID: 11309301
Guo M, Ren J, House M G, Qi Y, Brock M V, Herman J G. Accumulation of promoter methylation suggests epigeneticprogression in squamous cell carcinoma of the esophagus.Clin Cancer Res, 2006, 12(15): 4515―4522
PMID: 16899597
Guo M, Ren J, Brock M V, Herman J G, Carraway H E. Promoter methylation of HIN-1in the progression to esophageal squamous cancer.Epigenetics, 2008, 3(6): 336―341
PMID: 19098448
Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton J P, David S, Agarwal R, Selaru F M, Sato F, Abraham J M, Beer D G, Mori Y, Shimada Y, Meltzer S J. Promoter hypermethylationof CDH13 is a common, early event in human esophageal adenocarcinogenesisand correlates with clinical risk factors.Int J Cancer, 2008, 123(10): 2331―2336
PMID: 18729198
Jin Z, Hamilton J P, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Beer D G, Agarwal R, Abraham J M, Meltzer S J. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associatedesophageal neoplastic progression.CancerEpidemiol Biomarkers Prev, 2008, 17(1): 111―117
PMID: 18199717
Jin Z, Mori Y, Hamilton J P, Olaru A, Sato F, Yang J, Ito T, Kan T, Agarwal R, Meltzer S J. Hypermethylation of the somatostatin promoter is a common, earlyevent in human esophageal carcinogenesis.Cancer, 2008, 112(1): 43―49
PMID: 17999418
Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, Mori Y, Mantzur C, Paun B, Hamilton J P, Ito T, Wang S, David S, Agarwal R, Beer D G, Abraham J M, Meltzer S J. Hypermethylation of tachykinin-1 is a potential biomarker in humanesophageal cancer.Clin Cancer Res, 2007, 13(21): 6293―6300
PMID: 17975140
Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton J P, Kan T, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Hypermethylation of the nel-like1 gene is a common and early event and is associated with poor prognosisin early-stage esophageal adenocarcinoma.Oncogene, 2007, 26(43): 6332―6340
PMID: 17452981
Kuester D, Dar A A, Moskaluk C C, Krueger S, Meyer F, Hartig R, Stolte M, Malfertheiner P, Lippert H, Roessner A, El-Rifai W, Schneider-Stock R. Early involvement of death-associatedprotein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association withclinical progression.Neoplasia, 2007, 9(3): 236―245
PMID: 17401463
Hamilton J P, Sato F, Jin Z, Greenwald B D, Ito T, Mori Y, Paun B C, Kan T, Cheng Y, Wang S, Yang J, Abraham J M, Meltzer S J. Reprimo methylation is apotential biomarker of Barrett's-Associated esophageal neoplasticprogression.Clin Cancer Res, 2006, 12(22): 6637―6642
PMID: 17121882
Anupam K, Tusharkant C, Gupta S D, Ranju R. Loss of disabled-2 expression is an early event in esophagealsquamous tumorigenesis.World J Gastroenterol, 2006, 12(37): 6041―6045
PMID: 17009406
Clément G, Braunschweig R, Pasquier N, Bosman F T, Benhattar J. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation.J Pathol, 2006, 208(1): 100―107
PMID: 16278815
Zou H, Osborn N K, Harrington J J, Klatt K K, Molina J R, Burgart L J, Ahlquist D A. Frequent methylation of eyes absent 4 gene in Barrett's esophagusand esophageal adenocarcinoma.Cancer EpidemiolBiomarkers Prev, 2005, 14(4): 830―834
PMID: 15824152
Campbell N P, Villaflor V M. Neoadjuvant treatment of esophageal cancer.World J Gastroenterol, 2010, 16(30): 3793―3803
PMID: 20698042
Hyngstrom J R, Posner M C. Neoadjuvantstrategies for the treatment of locally advanced esophageal cancer.J Surg Oncol, 2010, 101(4): 299―304
PMID: 20187065
Kim M P, Correa A M, Lee J, Rice D C, Roth J A, Mehran R J, Walsh G L, Ajani J A, Maru D M, Chang J Y, Marom E M, Macapinlac H A, Lee J H, Vaporciyan A A, Rice T, Swisher S G, Hofstetter W L. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery:an orphan status.Ann Thorac Surg, 2010, 90(3): 884―890, discussion 890―891
PMID: 20732513
Metzger R, Heukamp L, Drebber U, Bollschweiler E, Zander T, Hoelscher A H, Warnecke-Eberz U. CUL2 and STK11 as novel response-predictivegenes for neoadjuvant radiochemotherapy in esophageal cancer.Pharmacogenomics, 2010, 11(8): 1105―1113
PMID: 20712528
Esteller M, Garcia-Foncillas J, Andion E, Goodman S N, Hidalgo O F, Vanaclocha V, Baylin S B, Herman J G. Inactivationof the DNA-repair gene MGMT and the clinical response of gliomas toalkylating agents.N Engl J Med, 2000, 343(19): 1350―1354
PMID: 11070098
Rivera A L, Pelloski C E, Gilbert M R, Colman H, De La Cruz C, Sulman E P, Bekele B N, Aldape K D. MGMT promotermethylation is predictive of response to radiotherapy and prognosticin the absence of adjuvant alkylating chemotherapy for glioblastoma.Neuro Oncol, 2010, 12(2): 116―121
PMID: 20150378
Hamilton J P, Sato F, Jin Z, Greenwald B D, Ito T, Mori Y, Paun B C, Kan T, Cheng Y, Wang S, Yang J, Abraham J M, Meltzer S J. Reprimo methylation is apotential biomarker of Barrett's-Associated esophageal neoplasticprogression.Clin Cancer Res, 2006, 12(22): 6637―6642
PMID: 17121882
Hamilton J P, Sato F, Greenwald B D, Suntharalingam M, Krasna M J, Edelman M J, Doyle A, Berki A T, Abraham J M, Mori Y, Kan T, Mantzur C, Paun B, Wang S, Ito T, Jin Z, Meltzer S J. Promoter methylation and response to chemotherapy andradiation in esophageal cancer.Clin GastroenterolHepatol, 2006, 4(6): 701―708
PMID: 16678495
Mandelker D L, Yamashita K, Tokumaru Y, Mimori K, Howard D L, Tanaka Y, Carvalho A L, Jiang W W, Park H L, Kim M S, Osada M, Mori M, Sidransky D. PGP9.5 promoter methylationis an independent prognostic factor for esophageal squamous cell carcinoma.Cancer Res, 2005, 65(11): 4963―4968
PMID: 15930319
Li L W, Yu X Y, Yang Y, Zhang C P, Guo L P, Lu S H. Expression of esophageal cancer related gene 4 (ECRG4),a novel tumor suppressor gene, in esophageal cancer and its inhibitoryeffect on the tumor growth in vitro and in vivo.Int J Cancer, 2009, 125(7): 1505―1513
PMID: 19521989
Brock M V, Gou M, Akiyama Y, Muller A, Wu T T, Montgomery E, Deasel M, Germonpré P, Rubinson L, Heitmiller R F, Yang S C, Forastiere A A, Baylin S B, Herman J G. Prognostic importance of promoter hypermethylationof multiple genes in esophageal adenocarcinoma.Clin Cancer Res, 2003, 9(8): 2912―2919
PMID: 12912936
Kawakami K, Brabender J, Lord R V, Groshen S, Greenwald B D, Krasna M J, Yin J, Fleisher A S, Abraham J M, Beer D G, Sidransky D, Huss H T, Demeester T R, Eads C, Laird P W, Ilson D H, Kelsen D P, Harpole D, Moore M B, Danenberg K D, Danenberg P V, Meltzer S J. Hypermethylated APC DNA in plasma and prognosis of patients withesophageal adenocarcinoma.J Natl CancerInst, 2000, 92(22): 1805―1811
PMID: 11078757
Lee E J, Lee B B, Kim J W, Shim Y M, Hoseok I, Han J, Cho E Y, Park J, Kim D H. Aberrant methylation of Fragile Histidine Triad gene is associatedwith poor prognosis in early stage esophageal squamous cell carcinoma.Eur J Cancer, 2006, 42(7): 972―980
PMID: 16564166
Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton J P, Kan T, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Hypermethylation of the nel-like1 gene is a common and early event and is associated with poor prognosisin early-stage esophageal adenocarcinoma. Oncogene, 2007, 26(43): 6332―6340
Ohta M, Mimori K, Fukuyoshi Y, Kita Y, Motoyama K, Yamashita K, Ishii H, Inoue H, Mori M, Olaru A, David S, Agarwal R, Abraham J M, Beer D, Montgomery E, Meltzer S J. Clinical significance ofthe reduced expression of G protein gamma 7 (GNG7) in oesophagealcancer.Br J Cancer, 2008, 98(2): 410―417
PMID: 18219292
Lee E J, Lee B B, Han J, Cho E Y, Shim Y M, Park J, Kim D H. CpG islandhypermethylation of E-cadherin (CDH1) and integrin alpha4 is associatedwith recurrence of early stage esophageal squamous cell carcinoma.Int J Cancer, 2008, 123(9): 2073―2079
PMID: 18697202
Zare M, Jazii F R, Alivand M R, Nasseri N K, Malekzadeh R, Yazdanbod M. Qualitative analysis of Adenomatous Polyposis Coli promoter:hypermethylation, engagement and effects on survival of patients withesophageal cancer in a high risk region of the world, a potentialmolecular marker.BMC Cancer, 2009, 9: 24
PMID: 19149902
[1] Yi Cao. Environmental pollution and DNA methylation: carcinogenesis, clinical significance, and practical applications[J]. Front. Med., 2015, 9(3): 261-274.
[2] Sandy Leung-Kuen Au, Irene Oi-Lin Ng, Chun-Ming Wong. Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins[J]. Front Med, 2013, 7(2): 231-241.
[3] Qingqing Xu, Xi Wu, Yuyu Xiong, Qinghe Xing, Lin He, Shengying Qin. Pharmacogenomics can improve antipsychotic treatment in schizophrenia[J]. Front Med, 2013, 7(2): 180-190.
[4] Jing Liu, Jinbo Yue, Ligang Xing, Jinming Yu. Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer[J]. Front Med, 2013, 7(2): 172-179.
[5] Chunquan CAI, Qian LI, Qingjiang ZHANG, Changhong SHEN. Fibrous dysplasia involving the calvarium in children?[J]. Front Med Chin, 2009, 3(2): 211-215.
[6] Hong LI, Shaoqin CHEN, Yi SHU, Yongjun CHEN, Ying SU, Xin WANG, Shengquan ZOU. Effects of hydralazine and valproate on the expression of E-cadherin gene and the invasiveness of QBC939 Cells[J]. Front Med Chin, 2009, 3(2): 153-157.
Full text